ALBO:NSD-Albireo Pharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 35.77

Change

+1.49 (+4.35)%

Market Cap

USD 0.65B

Volume

0.40M

Average Target Price

USD 61.50 (+71.93%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.37 (-0.63%)

USD56.65B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

-17.51 (-3.34%)

USD55.87B 20.76 16.02
MRNA Moderna, Inc

-2.47 (-2.44%)

USD39.98B N/A N/A
SGEN Seagen Inc

-3.44 (-2.05%)

USD30.08B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.50 (+0.41%)

USD26.83B 28.36 26.40
RPRX Royalty Pharma plc

-0.62 (-1.54%)

USD25.13B 23.05 9.48
BNTX BioNTech SE

-4.63 (-4.35%)

USD25.06B -99,999.99 N/A
BGNE BeiGene, Ltd

-17.60 (-6.43%)

USD24.70B N/A N/A
GMAB Genmab A/S

-0.81 (-2.25%)

USD23.92B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALBO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.72% 71% C- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.72% 71% C- 78% C+
Trailing 12 Months  
Capital Gain 81.30% 75% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.30% 75% C 85% B
Trailing 5 Years  
Capital Gain 232.40% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 232.40% 88% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 33.33% N/A N/A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.33% N/A N/A 86% B
Risk Return Profile  
Volatility (Standard Deviation) 58.73% N/A N/A 18% F
Risk Adjusted Return 56.75% N/A N/A 76% C
Market Capitalization 0.65B 68% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.17 59% F 40% F
Price / Cash Flow Ratio -12.36 69% D+ 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -57.66% 57% F 20% F
Return on Invested Capital -56.64% 56% F 17% F
Return on Assets -21.94% 61% D- 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.75 58% F 47% F
Short Percent 3.72% 69% D+ 47% F
Beta 1.63 43% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector